Cargando…
Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602541/ http://dx.doi.org/10.1007/s40278-021-05501-x |
| _version_ | 1784601597792223232 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8602541 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86025412021-11-19 Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports Reactions Weekly Case Report Springer International Publishing 2021-11-20 2021 /pmc/articles/PMC8602541/ http://dx.doi.org/10.1007/s40278-021-05501-x Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Case Report Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports |
| title | Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports |
| title_full | Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports |
| title_fullStr | Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports |
| title_full_unstemmed | Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports |
| title_short | Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports |
| title_sort | alemtuzumab/natalizumab/ocrelizumab: covid-19: 3 case reports |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602541/ http://dx.doi.org/10.1007/s40278-021-05501-x |